swisspartners Ltd. Purchases New Holdings in cbdMD, Inc. (NYSEAMERICAN:YCBD)

swisspartners Ltd. acquired a new position in cbdMD, Inc. (NYSEAMERICAN:YCBD) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 120,000 shares of the company’s stock, valued at approximately $501,000. swisspartners Ltd. owned 0.23% of cbdMD at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. BlackRock Inc. increased its stake in cbdMD by 0.7% in the fourth quarter. BlackRock Inc. now owns 456,888 shares of the company’s stock worth $1,347,000 after purchasing an additional 3,315 shares during the period. Acadian Asset Management LLC purchased a new position in cbdMD in the 1st quarter worth about $44,000. ExodusPoint Capital Management LP bought a new stake in cbdMD during the 4th quarter valued at about $34,000. Engineers Gate Manager LP purchased a new stake in cbdMD in the 4th quarter valued at about $52,000. Finally, Warberg Asset Management LLC bought a new position in cbdMD in the 4th quarter worth about $59,000. 19.34% of the stock is owned by institutional investors and hedge funds.

Separately, Zacks Investment Research upgraded cbdMD from a “sell” rating to a “hold” rating in a report on Thursday, April 1st.

Shares of YCBD traded up $0.02 during mid-day trading on Friday, hitting $3.32. 2,091 shares of the company traded hands, compared to its average volume of 792,538. The company has a market capitalization of $187.31 million, a P/E ratio of -4.34 and a beta of 1.72. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.06 and a quick ratio of 4.43. The firm’s 50 day simple moving average is $2.88. cbdMD, Inc. has a 1-year low of $1.41 and a 1-year high of $6.83.

cbdMD (NYSEAMERICAN:YCBD) last announced its quarterly earnings data on Wednesday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.21). cbdMD had a negative net margin of 79.89% and a negative return on equity of 35.34%. On average, sell-side analysts predict that cbdMD, Inc. will post -0.09 earnings per share for the current fiscal year.

About cbdMD

cbdMD, Inc produces and distributes various cannabidiol (CBD) products. It owns and operates consumer hemp-based CBD brands, such as cbdMD and Paw CBD. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name.

Recommended Story: How Do Front-End Loads Impact an Investment?

Want to see what other hedge funds are holding YCBD? Visit to get the latest 13F filings and insider trades for cbdMD, Inc. (NYSEAMERICAN:YCBD).

Institutional Ownership by Quarter for cbdMD (NYSEAMERICAN:YCBD)

Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with's FREE daily email newsletter.